JPRN-jRCT2080223482
Completed
Phase 3
A Phase III Study of SI-613 in Patients with Knee Osteoarthritis (confirmatory study)
SEIKAGAKU CORPORATIO0 sites440 target enrollmentStarted: March 14, 2017Last updated:
ConditionsKnee osteoarthritis
Overview
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- SEIKAGAKU CORPORATIO
- Enrollment
- 440
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 40age old to <= 75age old (—)
- Sex
- All
Inclusion Criteria
- •Diagnosis of osteoarthritis of the knee according to American College of Rheumatology criteria at the time of screening.
- •Kellgren\-Lawrence score grade 2 or 3 in an Antero\-posterior weight\-bearing x\-ray of the target knee joint in the standing position taken at the time of screening.
- •Subjects who are willing to discontinue pain medication except as permitted per protocol from the start date of screening to the end of Week 24 after the first injection (using acetaminophen as a rescue medication is permitted for breakthrough pain control).
Exclusion Criteria
- •Secondary OA resulting from trauma or the other diseases in the target knee
- •Subjects who have pain in lower extremity other than knee OA if it would interfere with the evaluation of the target knee or have OA of the hip or ankle at screening and Week 0 before injection.
Investigators
Similar Trials
Completed
Phase 2
A Phase II Study of SI-613 in Patients with Knee OsteoarthritisKnee OsteoarthritisJPRN-UMIN000010167SEIKAGAKU CORPORATIO120
Completed
Not Applicable
A Phase II Study of SI-613 in Patients with Knee Osteoarthritis (repeat-dose study)JPRN-UMIN000015858SEIKAGAKU CORPORATIO160
Completed
Not Applicable
A Phase III Study of SI-6603 in Patients with Lumbar Disc Herniatioumbar Disc HerniationJPRN-UMIN000007239SEIKAGAKU CORPORATIO160
Unknown
Phase 2
Study of SI000413 in Knee Osteoarthritis PatientsOsteoarthritis, KneeNCT01525758Dong-A Pharmaceutical Co., Ltd.152
Recruiting
Not Applicable
Evaluation of knee function and safety after treatment of knee articular cartilage damage with iPS-cell-derived cartilage.JPRN-jRCT1050220051Matsuda Shuichi4